Applied Clinical Trials
The FDA issued guidances in February that outlines its recommendations for developing and approving biosimilar therapies.
The Food and Drug Administration issued guidances in February that outlines its recommendations for developing and approving biosimilar therapies. The announcement came the same day that FDA officials discussed new user fees for biosimilars and generic drugs at a Congressional hearing. Three separate draft guidances map out the scientific considerations, quality analytical factors, and other regulatory issues for bringing to market new therapeutic proteins that are similar, "but not the same" as a reference product.
The documents describe a step-wise approval pathway, starting with extensive analytical, physico-chemical, and biological characterization data that can demonstrate a high degree of similarity. FDA will evaluate the data and then provide advice to the sponsor on the extent and scope of animal and human testing needed to show biosimilarity. FDA will consider multiple factors in making study determinations, including product complexity, formulation, stability, structure-function relationships, manufacturing process, and clinical experience with the reference product.
Unlike European regulators, FDA decided not to issue guidances for developing biosimilars in different drug product classes. To avoid redundant and unnecessary animal and clinical testing, sponsors will be permitted to use a non-US licensed comparator in certain studies, with appropriate bridging data. Most applications, though, will require some additional clinical trials.
Once FDA determines that a product is biosimilar, the sponsor can opt to demonstrate interchangeability—requiring additional switching studies to show that changing to the new product does not affect safety and efficacy.
FDA expects to be inundated with comments on these proposals and plans a public meeting. Meanwhile, staffers are holding dozens of pre-IND meetings with sponsors and encouraging all prospective biosimilar makers to seek early advice.
More information is available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm291232.htm. —Jill Wechsler
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.